Zhonglin Lv et al. found that myeloid loss of EFTUD2 led to impaired activation of macrophage NF-κB and ERK, which reduced the release of pro-inflammatory cytokines and growth factors, and ultimately inhibited tumor development and progression [24]. This evidence concerns the gene EFTUD2 and neoplasm.